Eris Lifesciences Limited

NSE ERIS.NS

Eris Lifesciences Limited Price to Earnings Ratio (P/E) on January 14, 2025: 42.82

Eris Lifesciences Limited Price to Earnings Ratio (P/E) is 42.82 on January 14, 2025, a 31.87% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Eris Lifesciences Limited 52-week high Price to Earnings Ratio (P/E) is 53.11 on December 10, 2024, which is 24.04% above the current Price to Earnings Ratio (P/E).
Eris Lifesciences Limited 52-week low Price to Earnings Ratio (P/E) is 29.15 on April 04, 2024, which is -31.93% below the current Price to Earnings Ratio (P/E).
Eris Lifesciences Limited average Price to Earnings Ratio (P/E) for the last 52 weeks is 38.65.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NSE: ERIS.NS

Eris Lifesciences Limited

CEO	Mr. Amit Indubhushan Bakshi
IPO Date	June 30, 2017
Location	India
Headquarters	Shivarth Ambit
Employees	3,620
Sector	Health Care
Industries Pharmaceuticals

Description

Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, antidiabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Key trends

Past 5 years